BMEA: Promising phase II data for novel diabetes therapies, with key readouts due by next year
The presentation highlighted a focused pipeline with a first-in-class menin inhibitor for diabetes and a next-generation GLP-1 agonist, both showing promising phase II results in efficacy and safety. Key readouts and regulatory milestones are expected by the end of next year.Based on Biomea Fusion…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.